Skip to main content
. 2013 Jan 24;168(4):850–862. doi: 10.1111/j.1476-5381.2012.02214.x

Figure 3.

Figure 3

Effect of PAL-313, (+)MDMA, PAL-287, (–)MDMA and fenfluramine on ICSS. Left panels (A, C, E, G, I) show drug effects on full ICSS frequency–rate curves. Right panels (B, D, F, H, J) show summary ICSS data expressed as percent pre-drug baseline number of reinforcers delivered across all frequencies. Other details as in Figure 1. All data show mean ± SEM for five to seven rats (except for 10.0 mg kg−1 PAL-287, n = 3). Statistical results for data in left panels are as follows: (A) PAL-313 (n = 5): significant main effect of frequency [F(9,36) = 44.9, P < 0.001] but not dose [F(3,12) = 2.9, P = 0.079]. There was a significant interaction [F(27,108) = 3.8, P = < 0.001]. C. (+)MDMA: significant main effect of frequency [F(9,36) = 51.0, P < 0.001], dose [F(4,16) = 3.6, P = 0.028] and significant interaction [F(36,144) = 4.0, P < 0.001]. (E) PAL-287 0.32–3.2 mg kg−1 (n = 5): significant main effect of frequency [F(9,36) = 71.6, P < 0.001], dose [F(3,12) = 4.7, P < 0.021] and significant interaction [F(27,108) = 3.9, P = < 0.001]. PAL-287 10.0 mg kg−1 (n = 3): significant main effect of frequency [F(9,18) = 27.0, P < 0.001] but not dose [F(1,2) = 3.1, P = 0.222]. There was a significant interaction [F(9,18) = 21.7, P = < 0.001]. Additional rats were not tested at 10 mg kg−1 due to lethality. (G) (–)MDMA: significant main effect of frequency [F(9,36) = 72.4, P < 0.001] but not dose [F(3,12) = 3.4, P = 0.052]. There was a significant interaction [F(27,108) = 3.8, P < 0.001]. (I) Fenfluramine (n = 7): significant main effect of frequency [F(9,54) = 70.3, P < 0.001], dose [F(3,18) = 33.5, P < 0.001] and significant interaction [F(27,162) = 9.1, P = < 0.001].